2. About Us…

3. About Us…

4. About Us…

5. About Us…

6. About Us…

7. Regulatory Approvals —● GOA I —● GOA II ● GOA III ● WALUJ ● BADDI I
LOCATION
DOSAGE FORM
APPROVALS
—● GOA I
—● TABLETS, CREAMS & OINTMENTS
—● US-FDA
● EU-GMP
—● TGA Australia
— ● MCC South Africa
● ANVISA – Brazil
—● GOA II
● STERILE PRODUCTS
Same as above
● GOA III
—● TABLETS
—● US-FDA
— ● EU-GMP
—● TGA Australia
● WALUJ
—● TABLETS
● Emerging Markets
● BADDI I
—● TABLETS, LIQUID ORALS
& TOOTHPASTES
● EU–GMP and
—● BADDI II
● TABLETS & CAPSULES
—● WHO GMP
● PATALGANGA
—● APIs
● US-FDA, TGA Australia
—● KILOLAB
● US-FDA, TGA Australia

8. Business Model INDIAN BUSINESS International Business Allied Services
Branded Generics
Active Pharmaceutical Ingredients (APIs) (Captive Consumption & Supply to end users)
INDIAN
BUSINESS
Regulated Markets Generics CRAMS
Emerging Markets Branded Generics
International
Business
AnaCipher - CRO for BA / BE Studies
- Analytical Services
Xtend Industrial Designers and Engineers
Allied
Services

9. Indian Formulation Business
TOP BRANDS
CYCLOPAM
FEBREX PLUS
SENSODENT K
ATM
OXIPOD
CITAL
SENSOFORM
CLOBEN G
SENSODENT KF
KARVOL PLUS
Marketing Divisions
Main Doctor Specialties
INDOCO
Multi Specialty Division
SPADE
GP, CP, ENT, Pediatrician
Warren ACE
Dentists
Warren NXGen
Dentists / Super specialties within Dentistry
SPERA
Gynecologists, General Practitioners
FOCUS
Consulting Physicians
INDOCO CND
Cardiologists, Diabetologists, Consulting Physicians
EXCEL
Ophthalmologists
ETERNA
Orthopedicians
IMPULSE / INSTITUTION
Private Corporate Hospitals & Govt. Institutions

10. Indian Business - Growth Drivers
Increasing income levels, rapid urbanization, changing lifestyle, rapid expansion in healthcare insurance sector, demand for quality healthcare services
Brand building and focus on sub-chronic segment
Penetration in Northern and Eastern Regions to achieve regional balance
New Products introductions
(Around 20 products including brand extensions every year)
Focus on developing sustainable prescription support from Doctors Specialties
Significant API contribution with expanded product basket and services

11. International Business
Revenue of
` 337 Crs in
Revenue contribution
(Europe 40%, USA 28%,
SA & ANZ 19%)
CRAMS, FDF, APIs
MAs / Dossier
Out-Licensing
Regulated Markets
( 87% of
Exports)
` 49 Crs in
Revenue Contribution
(Africa 8%, Asia 2%,
FWA 2%, Latam & Others 1% )
Promotion of Branded
Generics through
Distributors
Emerging Markets
( 13% of

12. International Business - Growth Drivers
Partnership and alliances
Niche Product pipeline in Ophthalmic space
Regulatory approvals from countries including US / Europe for manufacturing facilities and products
Own filing of ANDAs and Dossiers
Shift from CRAMS to supplies against own dossiers / marketing authorizations in regulated markets
Creation of own Intellectual Property through Patents and Trademarks
NDDS and new platform technologies for future commercial exploitation

13. Financials Particulars Quarter Ended Nine Months Ended Year Ended
(` in Lacs)
Particulars
Quarter Ended
Nine Months Ended
Year Ended
Gw %
Net Revenues
27221
25641
6.2
80110
72301
10.8
98212
PAT
1759
1898
(7.3)
5951
6134
(3.0)
8332
% to Net Sales
6.5
7.4
8.5
EBIDTA
3953
4276
(7.6)
12328
13015
(5.3)
17235
14.5
16.7
15.4
18.0
17.5
Operating Profit
3604
3295
9.4
10633
10533
0.9
14292
13.2
12.9
13.3
14.6
Earnings per
1.91
2.06
6.45
6.65
9.04
Share (EPS)
Face Value (Rs 2/-)

14. Share Holding Pattern and MCAP

15. Safe Harbor…
This presentation may include certain forward – looking statements and information that involve risks, uncertainties and assumptions based on current expectations, within the meaning of applicable laws and regulations. Forward – looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects” and similar expressions. Actual results could differ materially from those projected in forward looking statements and the company does not guarantee realization of these statements. Any forward looking statement or information contained in this presentation speaks only as of the date of the statements. The company also disclaims any obligation to revise any forward looking statements.
No part of this presentation may be reproduced, quoted or circulated without the prior approval from Indoco Remedies Limited.

16. Thank You